{
  "claims": [
    {
      "claim_id": "C01",
      "claim": "Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling that sensitizes tumors to immune checkpoint blockade.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.",
          "line_ref": "L42"
        },
        {
          "quote": "Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.",
          "line_ref": "L46"
        },
        {
          "quote": "Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.",
          "line_ref": "L39"
        }
      ],
      "caveat": "Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings."
    },
    {
      "claim_id": "C02",
      "claim": "Intratumoral mRNA vaccination expands the breadth of peptides presented on MHC-I, improving tumor visibility to T cells.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "Interferon-associated antigen processing and presentation pathways increase.",
          "line_ref": "L43"
        },
        {
          "quote": "A broader peptide repertoire appears on MHC-I, improving tumor visibility to T cells.",
          "line_ref": "L44"
        },
        {
          "quote": "Fraction of proteins represented in MHC-I peptidome: 40.6% vs 20.6% - Strong expansion of MHC-I-presented landscape",
          "line_ref": "L29"
        }
      ],
      "caveat": "Mouse model effects may not map one-to-one to all human tumors."
    },
    {
      "claim_id": "C03",
      "claim": "PD-L1 pathway activity increases following mRNA vaccination, creating a mechanistic rationale for combining with checkpoint blockade.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "PD-L1 pathway activity also increases, creating a rationale for combining with checkpoint blockade.",
          "line_ref": "L45"
        },
        {
          "quote": "PD-L1 expression fold-change in tumor tissue: 2.4x vs 1.0x - Checkpoint axis became more targetable",
          "line_ref": "L32"
        }
      ],
      "caveat": "The degree of PD-L1 upregulation may vary across different tumor types and individual patients."
    },
    {
      "claim_id": "C04",
      "claim": "Prior SARS-CoV-2 mRNA vaccination is associated with improved survival outcomes in metastatic patients receiving immune checkpoint inhibitor treatment.",
      "strength": "moderate",
      "evidence": [
        {
          "quote": "Retrospective human survival comparison p-value: p=0.01 - Vaccinated subgroup had improved survival under ICI treatment",
          "line_ref": "L30"
        },
        {
          "quote": "Human vaccinated subgroup: 43 patients",
          "line_ref": "L22"
        },
        {
          "quote": "Human unvaccinated subgroup: 87 patients",
          "line_ref": "L23"
        }
      ],
      "caveat": "The human analysis is retrospective and non-randomized; residual confounding is likely, and vaccination timing relative to ICI initiation varied across patients."
    }
  ]
}
